Host-microbiota Interactions in Auto-inflammatory Diseases

Inclusion Criteria: * Patients with autoinflammatory diseases aged \>12 years and followed in the CEREMAIA internal medicine department present for consultation or day hospital for a routine care visit. * FMF defined by the Eurofever/PRINTO criteria * or CAPS définie by the Eurofever/PRINTO criteria * or MKD defined by the Eurofever/PRINTO criteria * or - DADA2 defined by the presence of two mutations in the ADA2 gene with pathogenicity of at least ≥ 3 * or - HA20 defined by the presence of one TNFAIP3 mutation with pathogenicity of at least ≥ 3 * or - JAAD defined by the presence of one JAK1 mutation with pathogenicity of at least ≥ 3 * or Juvenile polyarthritis defined by the presence of one LACC1 mutation with pathogenicity of at least ≥ 3 * or - Unclassified AMI defined by: * Fever +/- systemic symptoms Recurrent * Biological inflammation (CRP\>20mg/l) in crisis or permanent * Absence of pathogenic mutation highlighted by current next-generation sequencing techniques in known autoinflammatory disease genes * Collection of non-opposition to participation in research and specific consent for the biological collection of the patient or their legal representative in the case of a minor patient * Lack of legal protection * Patients benefiting from a social security scheme Exclusion Criteria: * Antibiotic therapy within 3 months prior to inclusion. If antibiotic therapy was initiated between inclusion and stool collection (data collected on the self-administered questionnaire accompanying the stool collection), the analysis data performed prior to antibiotic therapy will be retained, and the stool will not be analyzed. * Current infection on the day of inclusion * No social security * Refusal to participate